OSR Holdings, Inc. (OSRH)
| Market Cap | 24.10M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -2.41M |
| Shares Out | 19.28M |
| EPS (ttm) | -0.54 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 33,610 |
| Open | 1.260 |
| Previous Close | 1.280 |
| Day's Range | 1.240 - 1.280 |
| 52-Week Range | 1.240 - 13.400 |
| Beta | 1.55 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 24, 2025 |
About OSRH
OSR Holdings, Inc. develops a portfolio of therapies and healthcare solutions in the United States, Europe, and South Korea. The company develops immunotherapy products, including VXM01, VXM04, VXM06, VXM08, and VXM10 for cancer treatment; DRT102-sp for the treatment of lumbar stenosis, disc herniaton, and spinal; DRT102-dt for dental augmentation; DRT102-nu for nonunion bone fracture; and DRT101 for osteoarthritis. It also provides medical devices. The company is based in Bellevue, Washington. [Read more]
Financial Performance
Financial StatementsNews
Darnatein to Present at 14th International BMP Conference Highlighting Advances in Regenerative Biologics
PHILADELPHIA , May 2, 2025 /PRNewswire/ -- Darnatein, a subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH), a biotechnology company advancing design-augmented biologics, announced today that it will pres...
Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology
SEOUL, South Korea , April 9, 2025 /PRNewswire/ -- Darnatein, a wholly-owned subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH), today announces that it has successfully secured an additional internation...
OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate Glioblastoma Therapies
SEOUL, South Korea , April 3, 2025 /PRNewswire/ -- OSR Holdings, Inc. ("OSR") (NASDAQ: OSRH), a global healthcare company focused on advancing innovative therapies, today announced that it has entered...
Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma
Results from Phase 2a Trial demonstrate a good safety and tolerability profile of VXM01 and Avelumab Combination Therapy in Glioblastoma, supporting further investigation of VXM01 BASEL, Switzerland ,...
OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer
BASEL, Switzerland, March 25, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for peopl...
OSR Holdings, Inc. and OSR Holdings Co., Ltd. Announce Completion of Business Combination
OSR Holdings, Inc. to Begin Trading on the Nasdaq Stock Market LLC on Tuesday, February 18, 2025 Under the symbol "OSRH" SEOUL, South Korea , Feb. 14, 2025 /PRNewswire/ -- OSR Holdings, Inc. (formerly...